ClinicalTrials.gg
CompletedNCT03215927ATtackMy-ILDUpdated Jan 7, 2025Results posted

Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease

A Phase 2 interventional study of Abatacept and Placebo in Myositis and Interstitial Lung Disease, sponsored by Rohit Aggarwal, MD. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-07.

Sponsored by Rohit Aggarwal, MD · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 78 studies in Myositis with a site in United States — 26 open to participants now, 32 under way, 6 of them phase 3. Myositis · United States.

Enrollment
36th of 56
20 · median 34
Started
2018
with 3 others
Phase 2
18 of 78
3 open now
Registered
29th of 78
by date

Among the 78 studies in Myositis with a site in United States, this one is the 36th largest by enrollment of the 56 interventional ones that give a count, is one of 4 that started in 2018, is one of 18 in phase 2, and was the 29th registered.

Myositis

216 studies on the registry are indexed under Myositis; 101 are open to participants now.

Browse Myositis studies →

Open to participants now

26 of the 78 studies in Myositis with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 72 Myositis studies recruiting now, 28 (39%) set no upper age limit and 36 (50%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Myositis with a site in United States, or all of them as a file.
02

Study summary

A randomized, controlled pilot trial to evaluate the efficacy and safety of subcutaneous Abatacept in treating interstitial lung disease associated with the anti-synthetase syndrome.

Read the detailed description

This is a proof of concept study to evaluate the efficacy, safety and tolerability of abatacept in Syn-ILD in a multi-center randomized, placebo-controlled 6-month (24-week) pilot study.

03

Conditions studied

  • Myositis
  • Interstitial Lung Disease

Keywords

  • ILD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years.
  2. Anti-synthetase syndrome defined as the patient possessing 1 antisynthetase autoantibody (Jo-1, PL-12, PL-7, KS, OJ, EJ, Zo) in the presence of ILD.
  3. ILD defined by radiographic (HRCT chest) findings of reticulation, honeycombing or ground glass opacities (GGO) without another plausible explanation. HRCT chest defining ILD for inclusion criteria, should be within last 1 year done as SOC.
  4. Active ILD (see Section 4.2).
  5. Baseline FVC a) % \<80% b) FVC 80-100% with > = 10% decline in FVC in last 12 months as minimal threshold of ILD severity (PFT done within last 3 months is acceptable for inclusion criteria determination)
  6. SOC therapy (IS) therapy:

    1. (prednisone or other forms of steroid in equivalent doses) OR one of the other immunosuppressive agent (either Mycophenolate (MMF) or Azathioprine (AZA) OR a combination of steroid and an immunosuppressive agent. MMF (maximum of 3 gm/day) or azathioprine (maximum of 200 mg/day).Goal is to start the trial drug (or placebo) soon after starting SOC (MMF/AZA/Steroids) and their doses are stable. Note that patients on steroids alone as well as not on steroids can be enrolled in the trial as well.
    2. Desired dose of the SOC therapy should be reached 4 weeks prior to first study visit (Visit 1). No dose changes are allowed 4 weeks prior to first study visit.
    3. Dose of concomitant therapy (SOC) cannot be changed during the 24 weeks of the trial unless safety/toxicity issues supervene.
    4. If on steroid, the steroid dose must be stable for 2 weeks prior to Visit 1.
  7. No other concomitant IS medications including methotrexate, cyclosporine, intravenous immunoglobulin (IVIG), tacrolimus, cyclophosphamide or tofacitinib.
  8. No concomitant biologic agents (i.e. rituximab, anti-tumor necrosis factor (TNF) agents, tocilizumab).
  9. Additional IS therapy: Patient cannot begin any new IS therapy or new steroid taper for the 24-week study period, except if severe clinical worsening (flare up) of the disease requiring rescue therapy occurs (i.e. documentation of worsening of PFT/HRCT and patient and physician determination of worsening). See section of rescue medication below for details.
  10. If the enrolling physician is planning to discontinue current IS agent or steroid before clinical trial, then following is required prior to Visit 1.

    Medication Washout Period methotrexate 4 weeks Other IS agent (e.g. azathioprine, cyclosporine, tacrolimus, leflunomide, mycophenolate mofetil) 4 weeks IVIg or cyclophosphamide 3 months rituximab 6 months infliximab or adalimumab 8 weeks glucocorticoids 2 weeks etanercept 2 weeks anakinra 1 week pirfenidone 4 weeks

  11. Men and women of must agree to use an acceptable method of during the trial period.
  12. Subject has provided written .

Exclusion criteria

Exclusion Criteria:

A patient will be excluded if any of the following Exclusion Criteria are met:

  1. Severe end stage lung disease:

    1. FVC ≤30% or (FEV1) ≤ 30% or
    2. Requirement of high O2 requirement ≥ 6 L/min at rest for >1 month before the study enrollment or
    3. Listed for lung transplantation or
    4. PI feels that ILD is severe and end stage fibrosis is such that there is low potential for improvement with any disease modifying intervention.
  2. Subjects under the age of 18.
  3. Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections (including but not limited to tuberculosis and atypical mycobacterial disease, and C, and herpes zoster, but excluding fungal infections of nail beds).
  4. Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening.
  5. Active tuberculosis (TB) requiring treatment within the previous 3 years. Patients should be screened for latent TB using purified protein derivative (PPD)/or quantiferon gold within last 1 year and, if positive, treated following local practice guidelines prior to initiating abatacept (ABT). Patients treated for active tuberculosis with no recurrence in 3 years are permitted.
  6. Primary or secondary immunodeficiency (history of or currently active) unless related to primary disease under investigation.
  7. Pregnant women or nursing (breast feeding) mothers.
  8. History of alcohol, drug or chemical abuse within 1 year prior to screening or any medical condition or physical or psychological state that the PI feels would not allow the subject to safely complete the study.
  9. Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization.
  10. Treatment with any other agent within 4 weeks (or 5 half-lives of the investigational drug, whichever is longer) of screening.
  11. Previous treatment with the following cell-depleting therapies, including investigational agents or approved therapies: CAMPATH, anti-CD4, anti-CD5, and anti-CD3.
  12. Previous treatment with ABT.
  13. History of severe allergic or anaphylactic reactions to monoclonal antibodies.
  14. Evidence of serious uncontrolled concomitant cardiovascular, nervous system, renal, hepatic, endocrine (include uncontrolled diabetes mellitus) or gastrointestinal disease (including complicated diverticulitis, ulcerative colitis, or Crohn's disease.)
  15. Evidence of concomitant lung disease which PI feels may interfere with clinical assessment of ILD for example severe active (COPD), asthma, occupational lung disease, pulmonary sarcoidosis, etc.
  16. Prisoners or subjects who are compulsory detained
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Subcutaneous placebo injection weekly for 24 weeks.

    Other: Placebo

  • Experimental
    Abatacept

    Subcutaneous injection of abatacept 125 mg weekly for 24 weeks. 24 week optional follow up phase all subjects receive abatacept 125 mg weekly.

    Drug: Abatacept

Interventions

  • Abatacept 125mg subcutaneous weekly

    Also known as: Orencia

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. % Predicted Forced Vital Capacity (FVC) Absolute Change

    The primary outcome criteria for efficacy will be the absolute change of % predicted FVC from the baseline visit to week 24 between the 2 treatment arms (SOC/placebo vs. SOC/Abatacept).

    Time frame: 24 Weeks

Secondary outcomes

  1. Time to Progression Free Survival

    The first occurrence of any of the following: death or lung transplantation or decline in % predicted FVC ≥ 10% or decline in % predicted FVC ≥ 5% with a decline in % predicted DLCO ≥ 15%

    Time frame: 48 weeks

  2. Comparison of Change in Patient Reported Dyspnea Scores (University of California San Diego Shortness of Breath Questionnaire)

    Measured by University of California San Diego Shortness of Breath Questionnaire (UCSD SOBQ) (range 0-120, higher score is worsening dyspnea).

    Time frame: 24 weeks

  3. Time to Improvement in % Predicted FVC ≥10%

    Comparison of percent predicted FVC results from pulmonary function tests from baseline to week 48. Improvement is defined as a % predicted FVC change ≥10%

    Time frame: 48 weeks

07

Results

Posted Jan 7, 2025

Participant flow

Subjects were enrolled from four clinical sites between June 2017 through May 2021.

Randomized, Placebo-controlled
Participant flow — Randomized, Placebo-controlled
MilestonePlaceboAbatacept
Started119
Completed118
Not completed01
Withdrew: Lack of efficacy01
Open Label Extension
Participant flow — Open Label Extension
MilestonePlaceboAbatacept
Started118
Completed97
Not completed21
Withdrew: Adverse event10
Withdrew: Lack of efficacy10
Withdrew: Death01

Outcome measures

Primary% Predicted Forced Vital Capacity (FVC) Absolute Change

The primary outcome criteria for efficacy will be the absolute change of % predicted FVC from the baseline visit to week 24 between the 2 treatment arms (SOC/placebo vs. SOC/Abatacept).

Time frame:
24 Weeks
Reported as:
Least squares mean · % predicted FVC
% Predicted Forced Vital Capacity (FVC) Absolute Change
% predicted FVCPlaceboAbatacept
% Predicted Forced Vital Capacity (FVC) Absolute Change-1.70 (-5.90 to 2.50)-2.05 (-6.97 to 2.87)
Statistical analysis
  • Placebo vs Abatacept · Mixed Models Analysis · p = <0.05 · Median difference (net): -2.55 · 95% CI -9.36 to 4.26The comparison difference value is µABT - µPlacebo.
SecondaryTime to Progression Free Survival

The first occurrence of any of the following: death or lung transplantation or decline in % predicted FVC ≥ 10% or decline in % predicted FVC ≥ 5% with a decline in % predicted DLCO ≥ 15%

Time frame:
48 weeks
Reported as:
Median · Weeks
Time to Progression Free Survival
WeeksPlaceboAbatacept
Time to Progression Free Survival27.71 (12.71 to 46.86)16.86 (15.36 to 34.93)
Statistical analysis
  • Placebo vs Abatacept · Regression, Cox · p = <0.05 · Hazard ratio (hr): 0.66 · 95% CI 0.16 to 2.77ABT is the numerator and Placebo is the denominator for the hazard ratios. The dispersion value given is the SE of the estimate on the natural log scale.
SecondaryComparison of Change in Patient Reported Dyspnea Scores (University of California San Diego Shortness of Breath Questionnaire)

Measured by University of California San Diego Shortness of Breath Questionnaire (UCSD SOBQ) (range 0-120, higher score is worsening dyspnea).

Time frame:
24 weeks
Reported as:
Least squares mean · score on a scale
Comparison of Change in Patient Reported Dyspnea Scores (University of California San Diego Shortness of Breath Questionnaire)
score on a scalePlaceboAbatacept
Comparison of Change in Patient Reported Dyspnea Scores (University of California San Diego Shortness of Breath Questionnaire)-4.59 (-15.54 to 6.36)3.20 (-8.86 to 15.26)
Statistical analysis
  • Placebo vs Abatacept · Mixed Models Analysis · p = <0.05 · Mean difference (net): 7.51 · 95% CI -8.80 to 23.83The comparison difference value is µABT - µPlacebo.
SecondaryTime to Improvement in % Predicted FVC ≥10%

Comparison of percent predicted FVC results from pulmonary function tests from baseline to week 48. Improvement is defined as a % predicted FVC change ≥10%

Time frame:
48 weeks
Reported as:
Median · weeks
Time to Improvement in % Predicted FVC ≥10%
weeksPlaceboAbatacept
Time to Improvement in % Predicted FVC ≥10%17.86 (9.86 to 25.86)11.86 (11.86 to 11.86)
Statistical analysis
  • Placebo vs Abatacept · Regression, Cox · p = <0.05 · Hazard ratio (hr): 0.42 · 95% CI 0.04 to 4.02ABT is the numerator and Placebo is the denominator for the hazard ratios. The dispersion value given is the SE of the estimate on the natural log scale.

Adverse events

Collected over Adverse events were collected from Baseline (week 0) through end of study Visit 5 (week 48). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/11 (0%)0/11 (0%)5/11 (45.5%)
Abatacept1/20 (5%)3/20 (15%)6/20 (30%)
Most frequent serious events
Most frequent serious events
EventPlaceboAbatacept
Respiratory FailureRespiratory, thoracic and mediastinal disorders0/111/20
DyspneaRespiratory, thoracic and mediastinal disorders0/111/20
HypoxiaRespiratory, thoracic and mediastinal disorders0/111/20
Most frequent other events
Showing 10 of 39
Most frequent other events
EventPlaceboAbatacept
Excessive bruisingBlood and lymphatic system disorders2/111/20
Sinus TachycardiaCardiac disorders2/110/20
NauseaGastrointestinal disorders2/110/20
Upper Respiratory InfectionInfections and infestations2/113/20
CoughRespiratory, thoracic and mediastinal disorders2/113/20
diarrheaGastrointestinal disorders0/113/20
Eye InfectionInfections and infestations0/111/9
Deceased lymphocyte countInvestigations0/112/20
Chest painCardiac disorders0/112/20
renal calculiRenal and urinary disorders0/112/20

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboAbataceptTotal
Mean55.95 ± 6.8751.56 ± 10.6953.98 ± 8.83
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAbataceptTotal
Female7411
Male459
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboAbataceptTotal
Hispanic or Latino000
Not Hispanic or Latino11920
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboAbataceptTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American112
White10717
More than one race000
Unknown or Not Reported000
Forced Vital Capacity (FVC) %
Forced Vital Capacity (FVC) %(%)PlaceboAbataceptTotal
Median61.0 (53.0 to 80.0)66.0 (49.0 to 68.5)63.5 (52.3 to 72.5)
08

Study locations

5 sites
  • Cedars-Sinai Medical Center
    Beverly Hills, California 90211, United States
  • University of Colorado Anschutz Medical Campus
    Denver, Colorado 80045, United States
  • John Hopkins Medical Center
    Baltimore, Maryland 21205, United States
  • Brigham & Women's Hospital
    Boston, Massachusetts 02115, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
09

References and documents

Publications

  • Kurasawa K, Nawata Y, Takabayashi K, Kumano K, Kita Y, Takiguchi Y, Kuriyama T, Sueishi M, Saito Y, Iwamoto I. Activation of pulmonary T cells in corticosteroid-resistant and -sensitive interstitial pneumonitis in dermatomyositis/polymyositis. Clin Exp Immunol. 2002 Sep;129(3):541-8. doi: 10.1046/j.1365-2249.2002.01933.x. PubMed 12197897 ↗
  • Israel-Assayag E, Fournier M, Cormier Y. Blockade of T cell costimulation by CTLA4-Ig inhibits lung inflammation in murine hypersensitivity pneumonitis. J Immunol. 1999 Dec 15;163(12):6794-9. PubMed 10586079 ↗
  • Jimenez-Alvarez L, Arreola JL, Ramirez-Martinez G, Ortiz-Quintero B, Gaxiola M, Reynoso-Robles R, Avila-Moreno F, Urrea F, Pardo A, Selman M, Zuniga J. The effect of CTLA-4Ig, a CD28/B7 antagonist, on the lung inflammation and T cell subset profile during murine hypersensitivity pneumonitis. Exp Mol Pathol. 2011 Dec;91(3):718-22. doi: 10.1016/j.yexmp.2011.09.010. Epub 2011 Sep 14. PubMed 21945736 ↗
  • Murata K, Dalakas MC. Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies. Am J Pathol. 1999 Aug;155(2):453-60. doi: 10.1016/s0002-9440(10)65141-3. PubMed 10433938 ↗
  • Nagaraju K, Raben N, Villalba ML, Danning C, Loeffler LA, Lee E, Tresser N, Abati A, Fetsch P, Plotz PH. Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells. Clin Immunol. 1999 Aug;92(2):161-9. doi: 10.1006/clim.1999.4743. PubMed 10444360 ↗
  • Cutolo M, Soldano S, Montagna P, Sulli A, Seriolo B, Villaggio B, Triolo P, Clerico P, Felli L, Brizzolara R. CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine production. Arthritis Res Ther. 2009;11(6):R176. doi: 10.1186/ar2865. Epub 2009 Nov 23. PubMed 19930661 ↗
  • Buch MH, Boyle DL, Rosengren S, Saleem B, Reece RJ, Rhodes LA, Radjenovic A, English A, Tang H, Vratsanos G, O'Connor P, Firestein GS, Emery P. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis. 2009 Jul;68(7):1220-7. doi: 10.1136/ard.2008.091876. Epub 2008 Sep 4. Erratum In: Ann Rheum Dis. 2011 Aug;70(8):1519. PubMed 18772191 ↗
  • Lumsden JM, Roberts JM, Harris NL, Peach RJ, Ronchese F. Differential requirement for CD80 and CD80/CD86-dependent costimulation in the lung immune response to an influenza virus infection. J Immunol. 2000 Jan 1;164(1):79-85. doi: 10.4049/jimmunol.164.1.79. PubMed 10604996 ↗
  • Platt AM, Gibson VB, Patakas A, Benson RA, Nadler SG, Brewer JM, McInnes IB, Garside P. Abatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cells. J Immunol. 2010 Aug 1;185(3):1558-67. doi: 10.4049/jimmunol.1001311. Epub 2010 Jul 2. PubMed 20601593 ↗
  • Mitsui T, Kuroda Y, Ueno S, Kaji R. The effects of FK506 on refractory inflammatory myopathies. Acta Neurol Belg. 2011 Sep;111(3):188-94. PubMed 22141281 ↗
  • Ochi S, Nanki T, Takada K, Suzuki F, Komano Y, Kubota T, Miyasaka N. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis. Clin Exp Rheumatol. 2005 Sep-Oct;23(5):707-10. PubMed 16173253 ↗
  • Ando M, Miyazaki E, Yamasue M, Sadamura Y, Ishii T, Takenaka R, Ito T, Nureki S, Kumamoto T. Successful treatment with tacrolimus of progressive interstitial pneumonia associated with amyopathic dermatomyositis refractory to cyclosporine. Clin Rheumatol. 2010 Apr;29(4):443-5. doi: 10.1007/s10067-009-1358-x. Epub 2010 Feb 4. PubMed 20130943 ↗
  • Takada K, Nagasaka K, Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity. 2005 Aug;38(5):383-92. doi: 10.1080/08916930500124023. PubMed 16227154 ↗
  • Wilkes MR, Sereika SM, Fertig N, Lucas MR, Oddis CV. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum. 2005 Aug;52(8):2439-46. doi: 10.1002/art.21240. PubMed 16052580 ↗
  • Guglielmo S, Bertinaria M, Rolando B, Crosetti M, Fruttero R, Yardley V, Croft SL, Gasco A. A new series of amodiaquine analogues modified in the basic side chain with in vitro antileishmanial and antiplasmodial activity. Eur J Med Chem. 2009 Dec;44(12):5071-9. doi: 10.1016/j.ejmech.2009.09.012. Epub 2009 Sep 15. PubMed 19811859 ↗
  • Kerola AM, Nieminen TV, Kauppi MJ, Kautiainen H, Puolakka K, Virta LJ, Kerola T. Increased risk of levothyroxine-treated hypothyroidism preceding the diagnosis of rheumatoid arthritis: a nationwide registry study. Clin Exp Rheumatol. 2014 Jul-Aug;32(4):455-9. Epub 2014 Jun 6. PubMed 24959977 ↗
  • Arabshahi B, Silverman RA, Jones OY, Rider LG. Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. J Pediatr. 2012 Mar;160(3):520-2. doi: 10.1016/j.jpeds.2011.11.057. Epub 2012 Jan 13. PubMed 22244459 ↗
  • Maeshima K, Kiyonaga Y, Imada C, Iwakura M, Hamasaki H, Haranaka M, Ishii K. Successful treatment of refractory anti-signal recognition particle myopathy using abatacept. Rheumatology (Oxford). 2014 Feb;53(2):379-80. doi: 10.1093/rheumatology/ket251. Epub 2013 Aug 6. No abstract available. PubMed 23920268 ↗
  • Elhai M, Meunier M, Matucci-Cerinic M, Maurer B, Riemekasten G, Leturcq T, Pellerito R, Von Muhlen CA, Vacca A, Airo P, Bartoli F, Fiori G, Bokarewa M, Riccieri V, Becker M, Avouac J, Muller-Ladner U, Distler O, Allanore Y; EUSTAR (EULAR Scleroderma Trials and Research group). Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis. 2013 Jul;72(7):1217-20. doi: 10.1136/annrheumdis-2012-202657. Epub 2012 Dec 19. PubMed 23253926 ↗
  • Mera-Varela A, Perez-Pampin E. Abatacept therapy in rheumatoid arthritis with interstitial lung disease. J Clin Rheumatol. 2014 Dec;20(8):445-6. doi: 10.1097/RHU.0000000000000084. No abstract available. PubMed 25417684 ↗
  • Khanna D, Mittoo S, Aggarwal R, Proudman SM, Dalbeth N, Matteson EL, Brown K, Flaherty K, Wells AU, Seibold JR, Strand V. Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) - Report from OMERACT CTD-ILD Working Group. J Rheumatol. 2015 Nov;42(11):2168-71. doi: 10.3899/jrheum.141182. Epub 2015 Mar 1. PubMed 25729034 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in May 2022, 52 months.

Results were first posted in Jan 2025, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2017
First posted
Jul 12, 2017
StartActual
Jan 1, 2018
Primary completionActual
May 30, 2022
CompletionActual
Jul 30, 2023
Results first posted
Jan 7, 2025
Last update
Jan 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03215927
Lead sponsor
Rohit Aggarwal, MD
Responsible party
Rohit Aggarwal, MD (Associate Professor, University of Pittsburgh) — Sponsor-investigator
First posted
Jul 12, 2017
Start date
Jan 1, 2018
Primary completion
May 30, 2022
Completion
Jul 30, 2023
Results posted
Jan 7, 2025
Last update
Jan 7, 2025

Study contacts

Rohit Aggarwal, MD
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion